Zurich Cantonal Bank
ATXS

Zurich Cantonal Bank’s Astria Therapeutics ATXS Stock Holding History

Zurich Cantonal Bank’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,249
Closed -$49.4K – 2567
2025
Q1 		$49.4K Hold
9,249
– – ﹤0.01% 2515
2024
Q4 		$82.7K Buy
+9,249
New +$98.2K ﹤0.01% 2489

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Zurich Cantonal Bank's ATXS Position: Q2 2025 in Review

Zurich Cantonal Bank sold out of Astria Therapeutics (ATXS) in Q2 2025, closing a stake of 9,249 shares — an estimated $49.4K sold.

Zurich Cantonal Bank first reported a position in ATXS in Q4 2024 and held it in 2 quarters. The position peaked at $82.7K in Q4 2024. 105 funds tracked by Wall St. Rank hold ATXS as of Q2 2025.

  • Zurich Cantonal Bank reported no remaining Astria Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Zurich Cantonal Bank sold 9,249 Astria Therapeutics shares in Q2 2025, an estimated $49.4K.
  • Zurich Cantonal Bank first reported a position in Astria Therapeutics in Q4 2024 and held it in 2 quarters.
  • Zurich Cantonal Bank's Astria Therapeutics position peaked at $82.7K in Q4 2024.
  • 105 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2025.

Based on Zurich Cantonal Bank's 13F filing for Q2 2025, filed 7 Aug 2025.